Indaptus Therapeutics is trading 5.17% down now at $1.10 amid weakness across biotechnology stocks.
- XBI, the sector ETF, is down 2.31% during regular trading.
- No new company-specific announcement dated August 28, 2026, was identified; the latest major company news was second-quarter results released August 13.
- An S-3 resale registration became effective August 25, potentially keeping supply concerns in focus; major-index performance was mixed and trading volume was unavailable.